Autoinflammatory Diseases and COVID-19 Vaccination: Analysis of SARS-CoV-2 Anti-S-RBD IgG Levels in a Cohort of Patients Receiving IL-1 Inhibitors
Abstract
:1. Introduction
2. Materials and Methods
2.1. Clinical and Demographic Characteristics of the Patients Included in the Study
2.2. Evaluation of Binding IgG Antibodies against the RBD Portion of the SARS-CoV-2 Spike Protein
2.3. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Galeazzi, M.; Gasbarrini, G.; Ghirardello, A.; Grandemange, S.; Hoffman, H.M.; Manna, R.; Podswiadek, M.; Punzi, L.; Sebastiani, G.D.; Touitou, I.; et al. Autoinflammatory syndromes. Clin. Exp. Rheumatol. 2006, 24, 79–85. [Google Scholar]
- Furer, V.; Eviatar, T.; Zisman, D.; Peleg, H.; Paran, D.; Levartovsky, D.; Zisapel, M.; Elalouf, O.; Kaufman, I.; Meidan, R.; et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and the general population: A multicentre study. Ann. Rheum. Dis. 2021, 80, 1330–1338. [Google Scholar] [CrossRef] [PubMed]
- Auroux, M.; Laurent, B.; Coste, B.; Massy, E.; Mercier, A.; Durieu, I.; Confavreux, C.B.; Lega, J.C.; Mainbourg, S.; Coury, F. Serological response to SARS-CoV-2 vaccination in patients with inflammatory rheumatic disease treated with disease-modifying anti-rheumatic drugs: A cohort study and a meta-analysis. Joint Bone Spine 2022, 89, 105380. [Google Scholar] [PubMed]
- Başaran, S.; Şimşek-Yavuz, S.; Meşe, S.; Çağatay, A.; Medetalibeyoğlu, A.; Öncül, O.; Özsüt, H.; Ağaçfidan, A.; Gül, A.; Eraksoy, H. The effect of tocilizumab, anakinra and prednisolone on antibody response to SARS-CoV-2 in patients with COVID-19: A prospective cohort study with multivariate analysis of factors affecting the antibody response. Int. J. Infect. Dis. 2021, 105, 756–762. [Google Scholar] [CrossRef] [PubMed]
- Alehashemi, S.; van Gelderen, E.; Rastegar, A.; de Jesus, A.A.; Goldbach-Mansky, R. Post-SARS-CoV-2 Vaccine Monitoring of Disease Flares in Autoinflammatory Diseases. J. Clin. Immunol. 2022, 42, 732–735. [Google Scholar] [CrossRef]
- Güven, S.C.; Karakaş, Ö.; Atalar, E.; Konak, H.E.; Akyüz Dağlı, P.; Kayacan Erdoğan, E.; Armağan, B.; Gök, K.; Doğan, İ.; Maraş, Y.; et al. A single-center COVID-19 vaccine experience with CoronaVac and BNT162b2 in familial Mediterranean fever patients. Int. J. Rheum. Dis. 2022, 25, 787–794. [Google Scholar] [CrossRef]
- Ozdede, A.; Guner, S.; Ozcifci, G.; Yurttas, B.; Toker Dincer, Z.; Atli, Z.; Uygunoğlu, U.; Durmaz, E.; Uçar, D.; Uğurlu, S.; et al. Safety of SARS-CoV-2 vaccination in patients with Behcet’s syndrome and familial Mediterranean fever: A cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine. Rheumatol. Int. 2022, 42, 973–987. [Google Scholar] [CrossRef]
- Braun-Moscovici, Y.; Kaplan, M.; Braun, M.; Markovits, D.; Giryes, S.; Toledano, K.; Tavor, Y.; Dolnikov, K.; Balbir-Gurman, A. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2. Ann. Rheum. Dis. 2021, 80, 1317–1321. [Google Scholar] [CrossRef]
- Padoan, A.; Bonfante, F.; Cosma, C.; Di Chiara, C.; Sciacovelli, L.; Pagliari, M.; Bortolami, A.; Costenaro, P.; Musso, G.; Basso, D.; et al. Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: Comparison with neutralization titers. Clin. Chem. Lab Med. 2021, 59, 1444–1452. [Google Scholar] [CrossRef]
- Padoan, A.; Cosma, C.; Della Rocca, F.; Barbaro, F.; Santarossa, C.; Dall’Olmo, L.; Galla, L.; Cattelan, A.; Cianci, V.; Basso, D.; et al. A cohort analysis of SARS-CoV-2 anti-spike protein receptor binding domain (RBD) IgG levels and neutralizing antibodies in fully vaccinated healthcare workers. Clin. Chem. Lab Med. 2022, 60, 1110–1115. [Google Scholar] [CrossRef]
- Strangfeld, A.; Schäfer, M.; Gianfrancesco, M.A.; Lawson-Tovey, S.; Liew, J.W.; Ljung, L.; Mateus, E.F.; Richez, C.; Santos, M.J.; Schmajuk, G.; et al. COVID-19 Global Rheumatology Alliance. Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann. Rheum. Dis. 2021, 80, 930–942. [Google Scholar] [CrossRef] [PubMed]
- Gianfrancesco, M.; Hyrich, K.L.; Al-Adely, S.; Carmona, L.; Danila, M.I.; Gossec, L.; Izadi, Z.; Jacobsohn, L.; Katz, P.; Lawson-Tovey, S.; et al. COVID-19 Global Rheumatology Alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann. Rheum. Dis. 2020, 79, 859–866. [Google Scholar] [CrossRef] [PubMed]
- Kyriazopoulou, E.; Poulakou, G.; Milionis, H.; Metallidis, S.; Adamis, G.; Tsiakos, K.; Fragkou, A.; Rapti, A.; Damoulari, C.; Fantoni, M.; et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: A double-blind, randomized controlled phase 3 trial. Nat. Med. 2021, 27, 1752–1760. [Google Scholar] [CrossRef]
- Ugurlu, S.; Akcin, R.; Ayla, A.Y.; Kocazeybek, B.; Oztas, M.; Can, G.; Mustafayeva, L.; Saltoglu, N.; Yilmaz, B.; Ozdogan, H. Antibody responses to inactivated and mRNA SARS-CoV-2 vaccines in familial Mediterranean fever patients treated with interleukin-1 inhibitors. Rheumatology 2022, 61, SI194–SI196. [Google Scholar] [CrossRef]
- Chioato, A.; Noseda, E.; Felix, S.D.; Stevens, M.; Del Giudice, G.; Fitoussi, S.; Kleinschmidt, A. Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1 beta-blocking antibody canakinumab: Results of an open-label, parallel group, randomized, single-center study. Clin. Vaccine Immunol. 2010, 17, 1952–1957. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brogan, P.; Hofer, M.; Kuemmerle-Deschner, J.; Lauwerys, B.; Speziale, A.; Abrams, K.; Leon, K.; Wei, X.; Laxer, R. Efficacy, safety, and post-vaccination antibody titer data in children with CAPS treated with Canakinumab. Pediatr. Rheumatol. 2015, 13, P1. [Google Scholar] [CrossRef] [Green Version]
- Heijstek, M.W.; Kamphuis, S.; Armbrust, W.; Swart, J.; Gorter, S.; de Vries, L.D.; Smits, G.P.; van Gageldonk, P.G.; Berbers, G.A.; Wulffraat, N.M. Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: A randomized trial. JAMA 2013, 309, 2449–2456. [Google Scholar] [CrossRef] [Green Version]
- Atagündüz, P.; Keser, G.; Soy, M. Interleukin-1 Inhibitors and Vaccination Including COVID-19 in Inflammatory Rheumatic Diseases: A Nonsystematic Review. Front. Immunol. 2022, 12, 734279. [Google Scholar] [CrossRef]
- Peet, C.J.; Papadopoulou, C.; Sombrito, B.R.M.; Wood, M.R.; Lachmann, H.J. COVID-19 and autoinflammatory diseases: Prevalence and outcomes of infection and early experience of vaccination in patients on biologics. Rheumatol. Adv. Pract. 2021, 5, rkab043. [Google Scholar] [CrossRef]
- Shechtman, L.; Lahad, K.; Livneh, A.; Grossman, C.; Druyan, A.; Giat, E.; Lidar, M.; Freund, S.; Manor, U.; Pomerantz, A.; et al. Safety of the BNT162b2 mRNA COVID-19 vaccine in patients with familial Mediterranean fever. Rheumatology 2022, 61, SI129–SI135. [Google Scholar] [CrossRef]
- Hasseli, R.; Richter, J.G.; Hoyer, B.F.; Lorenz, H.M.; Pfeil, A.; Regierer, A.C.; Schmeiser, T.; Strangfeld, A.; Voll, R.E.; Krause, A.; et al. COVID-19 task force of the German Society of Rheumatology collaborators; COVID-19-Rheuma.de collaborators. Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases. RMD Open 2023, 9, e002998. [Google Scholar] [PubMed]
- Simon, D.; Tascilar, K.; Schmidt, K.; Manger, B.; Weckwerth, L.; Sokolova, M.; Bucci, L.; Fagni, F.; Manger, K.; Schuch, F.; et al. Humoral and Cellular Immune Responses to SARS-CoV-2 Infection and Vaccination in Autoimmune Disease Patients with B Cell Depletion. Arthritis Rheumatol. 2022, 74, 33–37. [Google Scholar] [CrossRef] [PubMed]
- Bijlsma, J.W. EULAR COVID-19 Task Force. EULAR 2021 updated viewpoints on SARS-CoV-2 vaccination in patients with RMDs: A guidance to answer patients’ questions. Ann. Rheum. Dis. 2022, 81, 786–788. [Google Scholar] [CrossRef] [PubMed]
Demographic Characteristics | |
Patients, n | 43 |
Age, years (IQR) | 49 (37–60) |
Sex, n (%) | F, 26 (60.5); M, 17 (39.5) |
Type of SAID | |
AOSD, n (%) | 20 (46.5) |
FMF, n (%) | 17 (39.5) |
TRAPS, n (%) | 3 (7.0) |
CAPS, n (%) | 2 (4.7) |
Schnitzler, n (%) | 1 (2.3) |
Therapy | |
IL-1i (alone), n (%) | 18 (42.8) |
IL-1i + colchicine, n (%) | 6 (14) |
IL-1i + GCs < 10 mg/day, n (%) | 4 (9) |
IL-1i + JAK inhibitors, n (%) | 1 (2) |
IL-1i + methotrexate, n (%) | 2 (4) |
Colchicine, n (%) | 6 (14) |
GCs < 10 mg/day, n (%) | 1 (2) |
None, n (%) | 5 (11) |
Type of Vaccine | |
mRNA Comirnaty BNT162b2 (%) | 40 (93.0) |
mRNA Spikevax 1273 (%) | 2 (4.7) |
AZD1222 ChAdOx1 (%) | 1 (2.3) |
T3 | T6 | T9 | ||
---|---|---|---|---|
HC | S-RBD IgG, kBAU/L (IQR) | 2719 (724–4154) * | 275 (149–443) | 1077 (529–3409) * |
female | 2934 (1690–4796) * | 345 (137–514) | 1150 (529–3755) ° | |
male | 1878 (413–3334) # | 197 (147–296) | 828 (497–2943) # | |
SAID, patients | S-RBD IgG, kBAU/L (IQR) | 1400 (637–3206) * | 86 (45–198) | 2316 (1155–6681) * |
female | 1600 (852–3079) # | 74 (43–378) | 2316 (1155–6938) ° | |
male | 1261 (595–3548) # | 87 (42–152) | 1969 (594–5005) # |
Patients | 1 | 2 | 3 | 4 | 5 |
---|---|---|---|---|---|
Disease | TRAPS | FMF | AOSD | FMF | AOSD |
Date of the booster dose | 21 November | 21 November | 21 December | 21 November | 21 December |
Date of infection | 22 January | 22 May | 22 January | 22 March | 22 June |
COVID-19 symptoms | Sore throat, running nose | Fever < 38°, sore throat, cough, running nose | Fever < 38°, cough, running nose | Arthralgias, sore throat | Fever < 38°, sore throat |
Therapy during COVID-19 | CAM 300 mg/4 weeks | CAM 300 mg/4 weeks | Anakinra 200 mg/day | CAM 150 mg/4 weeks | Anakinra 100 mg/day |
Therapy for COVID-19 | Antipyretics | Antipyretics | Antipyretics | Monoclonal antibodies | Antipyretics |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bindoli, S.; Baggio, C.; Galozzi, P.; Vesentini, F.; Doria, A.; Cosma, C.; Padoan, A.; Sfriso, P. Autoinflammatory Diseases and COVID-19 Vaccination: Analysis of SARS-CoV-2 Anti-S-RBD IgG Levels in a Cohort of Patients Receiving IL-1 Inhibitors. J. Clin. Med. 2023, 12, 4741. https://doi.org/10.3390/jcm12144741
Bindoli S, Baggio C, Galozzi P, Vesentini F, Doria A, Cosma C, Padoan A, Sfriso P. Autoinflammatory Diseases and COVID-19 Vaccination: Analysis of SARS-CoV-2 Anti-S-RBD IgG Levels in a Cohort of Patients Receiving IL-1 Inhibitors. Journal of Clinical Medicine. 2023; 12(14):4741. https://doi.org/10.3390/jcm12144741
Chicago/Turabian StyleBindoli, Sara, Chiara Baggio, Paola Galozzi, Filippo Vesentini, Andrea Doria, Chiara Cosma, Andrea Padoan, and Paolo Sfriso. 2023. "Autoinflammatory Diseases and COVID-19 Vaccination: Analysis of SARS-CoV-2 Anti-S-RBD IgG Levels in a Cohort of Patients Receiving IL-1 Inhibitors" Journal of Clinical Medicine 12, no. 14: 4741. https://doi.org/10.3390/jcm12144741
APA StyleBindoli, S., Baggio, C., Galozzi, P., Vesentini, F., Doria, A., Cosma, C., Padoan, A., & Sfriso, P. (2023). Autoinflammatory Diseases and COVID-19 Vaccination: Analysis of SARS-CoV-2 Anti-S-RBD IgG Levels in a Cohort of Patients Receiving IL-1 Inhibitors. Journal of Clinical Medicine, 12(14), 4741. https://doi.org/10.3390/jcm12144741